<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aura Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/aura-biosciences-inc</link>
<description>Latest news and press releases for Aura Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 21:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aura-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683549b178dffbe2df0e45c8.webp</url>
<title>Aura Biosciences Inc</title>
<link>https://6ix.com/company/aura-biosciences-inc</link>
</image>
<item>
<title>Auranova Announces Closing of Private Placement of Flow-Through Shares</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/auranova-announces-closing-of-private-placement-of-flow-through-shares-1</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/auranova-announces-closing-of-private-placement-of-flow-through-shares-1</guid>
<pubDate>Tue, 07 Apr 2026 21:15:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - April 7, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") is pleased to announce that, further to its press release of April 1, 2026, it has closed a non-brokered private through the issuance of 3,061,200 common shares in the capital of the Company issued on a "flow-through" basis (each, a "FT Share") at a price of $0.49 per FT Share for aggregate gross proceeds of $1,499,988 (the "Offering").All securities issued pursuant.</description>
</item>
<item>
<title>Auranova Resources and Kenorland Minerals Commence Spring Drill Program at South Uchi Project</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/auranova-resources-and-kenorland-minerals-commence-spring-drill-program-at-south-uchi-project-2</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/auranova-resources-and-kenorland-minerals-commence-spring-drill-program-at-south-uchi-project-2</guid>
<pubDate>Wed, 01 Apr 2026 11:30:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - April 1, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") is pleased to announce that it has collared its first drill hole of the Phase 3 diamond drill program at the South Uchi Project (the "South Uchi Project"), located in the Red Lake District of Ontario and held under option from Kenorland Minerals Limited ("Kenorland").The first drill hole is a 1.2 km step-out along strike to the west of drill holes 25PADD31 and...</description>
</item>
<item>
<title>Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial</description>
</item>
<item>
<title>Auranova Resources and Kenorland Minerals Announce Upcoming 2026 Spring Drill Program at The South Uchi Project, Ontario</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/auranova-resources-and-kenorland-minerals-announce-upcoming-2026-spring-drill-program-at-the-south-uchi-project-ontario-2</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/auranova-resources-and-kenorland-minerals-announce-upcoming-2026-spring-drill-program-at-the-south-uchi-project-ontario-2</guid>
<pubDate>Wed, 18 Mar 2026 14:28:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 18, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") is pleased to announce the approval of a Phase 3 diamond drill program at the South Uchi Project (the "Project"), located in the Red Lake District of Ontario and held under an option agreement with Kenorland Minerals Limited ("Kenorland").2026 Spring Exploration ProgramThe Spring 2026 exploration program and budget have been approved by Auranova and will include up.</description>
</item>
<item>
<title>Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-participate-8th-annual-210500843</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-participate-8th-annual-210500843</guid>
<pubDate>Mon, 24 Nov 2025 21:05:00 GMT</pubDate>
<description>BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:50 a.m. ET. The live webcast of the fireside chat will be available on the “Investors & Media” page</description>
</item>
<item>
<title>Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-third-quarter-120000458</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-third-quarter-120000458</guid>
<pubDate>Thu, 13 Nov 2025 12:00:00 GMT</pubDate>
<description>Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential to Convert ‘Cold’ to ‘Hot’ Tumors, Supporting a Frontline Therapy Across the Bladder Cancer Spectrum; Phase 1b/2 Trial is on Track for Data Mid-2026 BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies</description>
</item>
<item>
<title>Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-participate-h-c-110000184</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-participate-h-c-110000184</guid>
<pubDate>Wed, 03 Sep 2025 11:00:00 GMT</pubDate>
<description>BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 11:00 a.m. ET. The live webcast of the presentation will be available on the “Investors & Media” page unde</description>
</item>
<item>
<title>Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-second-quarter-110000242</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-second-quarter-110000242</guid>
<pubDate>Wed, 13 Aug 2025 11:00:00 GMT</pubDate>
<description>Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Position Expected to Fund Operations into the First Half of 2027 BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function</description>
</item>
<item>
<title>Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-announces-pricing-public-133200696</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-announces-pricing-public-133200696</guid>
<pubDate>Thu, 15 May 2025 13:32:00 GMT</pubDate>
<description>BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up</description>
</item>
<item>
<title>Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-announces-proposed-public-101000570</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-announces-proposed-public-101000570</guid>
<pubDate>Thu, 15 May 2025 10:10:00 GMT</pubDate>
<description>BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying warrants to purchase shares of</description>
</item>
<item>
<title>Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-first-quarter-100100183</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-first-quarter-100100183</guid>
<pubDate>Thu, 15 May 2025 10:01:00 GMT</pubDate>
<description>First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Financial and Business Officer BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial res</description>
</item>
<item>
<title>Aura Biosciences to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-participate-upcoming-investor-200100654</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-participate-upcoming-investor-200100654</guid>
<pubDate>Thu, 01 May 2025 20:01:00 GMT</pubDate>
<description>BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference on Thursday, May 8, 2025.Fireside Chat at 9:30 a.m. ET. H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday</description>
</item>
<item>
<title>Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-announces-appointment-teresa-110000042</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-announces-appointment-teresa-110000042</guid>
<pubDate>Wed, 02 Apr 2025 11:00:00 GMT</pubDate>
<description>BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors, effective March 31, 2025. “I am pleased to welcome Teresa to our Board of Directors,” said Elisabet de los Pinos, Chief Executive Officer of Aura Bi</description>
</item>
<item>
<title>Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-fourth-quarter-200100146</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-fourth-quarter-200100146</guid>
<pubDate>Mon, 24 Mar 2025 20:01:00 GMT</pubDate>
<description>Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to Advance with Phase 3 CoMpass Trial Actively Enrolling Phase 2 Trial in Metastases to the Choroid Initiated Cash Position Expected to Support Operations into 2H 2026 BOSTON, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology</description>
</item>
<item>
<title>Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/positive-data-phase-1-trial-110000506</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/positive-data-phase-1-trial-110000506</guid>
<pubDate>Mon, 24 Mar 2025 11:00:00 GMT</pubDate>
<description>Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect Favorable Safety Profile; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients with NMIBC Aura Hosting Virtual Urologic Oncology Investor Event with Key Opinion Leaders Today at 4:30 pm Eastern T</description>
</item>
<item>
<title>Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-announces-additional-data-120000245</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-announces-additional-data-120000245</guid>
<pubDate>Mon, 03 Mar 2025 12:00:00 GMT</pubDate>
<description>Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that additional Phase 1 data evaluating bel-</description>
</item>
<item>
<title>Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference</guid>
<pubDate>Tue, 26 Nov 2024 05:00:00 GMT</pubDate>
<description>BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for</description>
</item>
<item>
<title>Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-third-quarter-2024-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-third-quarter-2024-financial-results-and-business-highlights</guid>
<pubDate>Tue, 12 Nov 2024 05:00:00 GMT</pubDate>
<description>Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start</description>
</item>
<item>
<title>Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/multiple-clinical-complete-responses-demonstrated-following-single-low-dose-administration-of-bel-sar-in-patients-with-non-muscle-invasive-bladder-cancer-nmibc-in-ongoing-phase-1-trial</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/multiple-clinical-complete-responses-demonstrated-following-single-low-dose-administration-of-bel-sar-in-patients-with-non-muscle-invasive-bladder-cancer-nmibc-in-ongoing-phase-1-trial</guid>
<pubDate>Thu, 17 Oct 2024 04:00:00 GMT</pubDate>
<description>Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in</description>
</item>
<item>
<title>Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma</title>
<link>https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-positive-phase-2-end-of-study-results-evaluating-bel-sar-as-a-first-line-treatment-for-early-stage-choroidal-melanoma</link>
<guid isPermaLink="true">https://6ix.com/company/aura-biosciences-inc/news/aura-biosciences-reports-positive-phase-2-end-of-study-results-evaluating-bel-sar-as-a-first-line-treatment-for-early-stage-choroidal-melanoma</guid>
<pubDate>Thu, 12 Sep 2024 04:00:00 GMT</pubDate>
<description>Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology</description>
</item>
</channel>
</rss>